Trial Profile

Clinical Trial to Evaluate Safety and Anti-tumor Activity of AKT Inhibitor, Ipatasertib,With Endocrine Therapy With/Without CDK 4/6 Inhibitor for Patients With Metastatic Hormone Receptor Positive Breast Cancer (TAKTIC)

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 18 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Fulvestrant (Primary) ; Ipatasertib (Primary) ; Letrozole (Primary) ; Palbociclib (Primary)
Indications Advanced breast cancer; HER2 negative breast cancer
Focus Adverse reactions
Acronyms TAKTIC

06 Jan 2023 Status changed from recruiting to active, no longer recruiting.
25 Oct 2021 Planned End Date changed from 30 Jun 2024 to 30 Dec 2024.
25 Oct 2021 Planned primary completion date changed from 30 Jun 2022 to 30 Dec 2022.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com